Glomerulus-on-a-Chip: Current Insights and Future Potential Towards Recapitulating Selectively Permeable Filtration Systems
Kotaro Doi,Hiroshi Kimura,Yukiko T Matsunaga,Teruo Fujii,Masaomi Nangaku
DOI: https://doi.org/10.2147/IJNRD.S344725
2022-03-10
International Journal of Nephrology and Renovascular Disease
Abstract:Kotaro Doi, 1 Hiroshi Kimura, 2 Yukiko T Matsunaga, 1 Teruo Fujii, 3 Masaomi Nangaku 4 1 Institute of Industrial Science, The University of Tokyo, Tokyo, Japan; 2 Department of Mechanical Engineering, School of Engineering, Tokai University, Kanagawa, Japan; 3 The University of Tokyo, Tokyo, Japan; 4 Division of Nephrology and Endocrinology, The University of Tokyo Graduate School of Medicine, Tokyo, Japan Correspondence: Masaomi Nangaku, Division of Nephrology and Endocrinology, The University of Tokyo Graduate School of Medicine, 7-3-1, Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan, Tel/Fax +81358009736, Email Glomerulopathy, characterized by a dysfunctional glomerular capillary wall, results in proteinuria, leading to end-stage renal failure and poor clinical outcomes, including renal death and increased overall mortality. Conventional glomerulopathy research, including drug discovery, has mostly relied on animal experiments because in-vitro glomerulus models, capable of evaluating functional selective permeability, was unavailable in conventional in-vitro cell culture systems. However, animal experiments have limitations, including time- and cost-consuming, multi-organ effects, unstable reproducibility, inter-species reliability, and the social situation in the EU and US, where animal experiments have been discouraged. Glomerulus-on-a-chip, a new in-vitro organ model, has recently been developed in the field of organ-on-a-chip research based on microfluidic device technology. In the glomerulus-on-a-chip, the podocytes and endothelial cells are co-cultured in a microfluidic device with physical stimuli that mimic the physiological environment to enhance cell function to construct a functional filtration barrier, which can be assessed by permeability assays using fluorescently labeled molecules including inulin and albumin. A combination of this glomerulus-on-a chip technology with the culture technology to induce podocytes and endothelial cells from the human pluripotent stem cells could provide an alternative organ model and solve the issue of animal experiments. Additionally, previous experiments have verified the difference in the leakage of albumin using differentiated podocytes derived from patients with Alport syndrome, such that it could be applied to intractable hereditary glomerulopathy models. In this review, we provide an overview of the features of the existing glomerulus-on-a-chip systems, focusing on how they can address selective permeability verification tests, and the challenges they involved. We finally discuss the future approaches that should be developed for solving those challenges and allow further improvement of glomerulus-on-a-chip technologies. Keywords: glomerulus, podocyte, selective permeability, microfluidic device, organ-on-a-chip This review article discusses an overview of the features of the existing glomerulus-on-a-chip techniques used for studying glomerulopathy, focusing on their selective permeability verification tests. Moreover, it discusses the challenges involved in the implementation of this technology as well as the approaches for solving those challenges. Glomerulopathy with high proteinuria is associated with end-stage renal failure requiring renal replacement therapy. It can also lead to an increased overall mortality and has implications for the global health economy. The glomerulus-on-a-chip method develops a new in-vitro organ model through which a functional filtration barrier is constructed by co-culturing podocytes and endothelial cells in a unique micro 3D space with physical stimuli that mimic the physiological environment. In addition, leakage assays can evaluate the selective permeability of filtration barrier with fluorescently labeled molecules including inulin and albumin. The integration of podocytes and endothelial cells derived from human pluripotent stem cells, including those from patients with intractable genetic diseases, into glomerulus-on-a-chip is expected to solve the problems of animal experiments and enable the development of efficient treatments for intractable genetic glomerular disorders. In recent years, kidney diseases have become a worldwide social problem. Kidney diseases reportedly affect approximately 10% of the world population, incurring high expenditure between 100,000 annually for dialysis treatment and kidney transplantation for patients with end-stage kidney disease. 1 Over the past two decades, guidelines, including diet (eg, low salt intake) to organ protection strategies (eg, renin-angiotensin-aldosterone system inhibitors), have significantly improved kidney disease management. 2,3 However, little progress has been made in the management and treatment of glomerular diseases, especially for -Abstract Truncated-